QDEL Quote, Financials, Valuation and Earnings

Perspective Therapeutics has a net margin of -25.21% compared to QuidelOrtho's net margin of --. QuidelOrtho's return on equity of -58.1% beat Perspective Therapeutics's return on equity of --.

QuidelOrtho has a consensus price target of $49.14, signalling upside risk potential of 74.95%. On the other hand Perspective Therapeutics has an analysts' consensus of $14.39 which suggests that it could grow by 502.21%. Given that Perspective Therapeutics has higher upside potential than QuidelOrtho, analysts believe Perspective Therapeutics is more attractive than QuidelOrtho.

QuidelOrtho has a beta of 0.432, which suggesting that the stock is 56.787% less volatile than S&P 500. In comparison Perspective Therapeutics has a beta of 1.199, suggesting its more volatile than the S&P 500 by 19.866%.

QuidelOrtho has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Perspective Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. QuidelOrtho pays -- of its earnings as a dividend. Perspective Therapeutics pays out -- of its earnings as a dividend.

QuidelOrtho quarterly revenues are $707.8M, which are larger than Perspective Therapeutics quarterly revenues of --. QuidelOrtho's net income of -$178.4M is lower than Perspective Therapeutics's net income of -$40.2M. Notably, QuidelOrtho's price-to-earnings ratio is -- while Perspective Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for QuidelOrtho is 0.68x versus 15.47x for Perspective Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

VolitionRX has a net margin of -25.21% compared to QuidelOrtho's net margin of -1226.82%. QuidelOrtho's return on equity of -58.1% beat VolitionRX's return on equity of --.

QuidelOrtho has a consensus price target of $49.14, signalling upside risk potential of 74.95%. On the other hand VolitionRX has an analysts' consensus of $2.92 which suggests that it could grow by 500.41%. Given that VolitionRX has higher upside potential than QuidelOrtho, analysts believe VolitionRX is more attractive than QuidelOrtho.

QuidelOrtho has a beta of 0.432, which suggesting that the stock is 56.787% less volatile than S&P 500. In comparison VolitionRX has a beta of 1.155, suggesting its more volatile than the S&P 500 by 15.463%.

QuidelOrtho has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. VolitionRX offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. QuidelOrtho pays -- of its earnings as a dividend. VolitionRX pays out -- of its earnings as a dividend.

QuidelOrtho quarterly revenues are $707.8M, which are larger than VolitionRX quarterly revenues of $474.5K. QuidelOrtho's net income of -$178.4M is lower than VolitionRX's net income of -$5.8M. Notably, QuidelOrtho's price-to-earnings ratio is -- while VolitionRX's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for QuidelOrtho is 0.68x versus 34.16x for VolitionRX. Usually stocks with elevated PS ratios are considered overvalued.

Catheter Precision has a net margin of -25.21% compared to QuidelOrtho's net margin of -4291.67%. QuidelOrtho's return on equity of -58.1% beat Catheter Precision's return on equity of -65.84%.

QuidelOrtho has a consensus price target of $49.14, signalling upside risk potential of 74.95%. On the other hand Catheter Precision has an analysts' consensus of -- which suggests that it could grow by 590.13%. Given that Catheter Precision has higher upside potential than QuidelOrtho, analysts believe Catheter Precision is more attractive than QuidelOrtho.

QuidelOrtho has a beta of 0.432, which suggesting that the stock is 56.787% less volatile than S&P 500. In comparison Catheter Precision has a beta of -0.775, suggesting its less volatile than the S&P 500 by 177.508%.

QuidelOrtho has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Catheter Precision offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. QuidelOrtho pays -- of its earnings as a dividend. Catheter Precision pays out -- of its earnings as a dividend.

QuidelOrtho quarterly revenues are $707.8M, which are larger than Catheter Precision quarterly revenues of $96K. QuidelOrtho's net income of -$178.4M is lower than Catheter Precision's net income of -$4.1M. Notably, QuidelOrtho's price-to-earnings ratio is -- while Catheter Precision's PE ratio is 0.40x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for QuidelOrtho is 0.68x versus 1.99x for Catheter Precision. Usually stocks with elevated PS ratios are considered overvalued.

Xtant Medical Holdings has a net margin of -25.21% compared to QuidelOrtho's net margin of -10.04%. QuidelOrtho's return on equity of -58.1% beat Xtant Medical Holdings's return on equity of -35.34%.

QuidelOrtho has a consensus price target of $49.14, signalling upside risk potential of 74.95%. On the other hand Xtant Medical Holdings has an analysts' consensus of $1.75 which suggests that it could grow by 243.14%. Given that Xtant Medical Holdings has higher upside potential than QuidelOrtho, analysts believe Xtant Medical Holdings is more attractive than QuidelOrtho.

QuidelOrtho has a beta of 0.432, which suggesting that the stock is 56.787% less volatile than S&P 500. In comparison Xtant Medical Holdings has a beta of -0.033, suggesting its less volatile than the S&P 500 by 103.341%.

QuidelOrtho has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xtant Medical Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. QuidelOrtho pays -- of its earnings as a dividend. Xtant Medical Holdings pays out -- of its earnings as a dividend.

QuidelOrtho quarterly revenues are $707.8M, which are larger than Xtant Medical Holdings quarterly revenues of $31.5M. QuidelOrtho's net income of -$178.4M is lower than Xtant Medical Holdings's net income of -$3.2M. Notably, QuidelOrtho's price-to-earnings ratio is -- while Xtant Medical Holdings's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for QuidelOrtho is 0.68x versus 0.58x for Xtant Medical Holdings. Usually stocks with elevated PS ratios are considered overvalued.